Biblio
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China. Bone Marrow Transplant. 2022.
Calcineurin Inhibitors Replacement by Ruxolitinib as Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
. Chronic graft-versus-host disease-related polymyositis and myocarditis: A case report and review of the literature. Transpl Immunol. 2022:101598.
Determining whether prophylactic antiviral treatment is necessary in HBsAg-negative/HBcAb-positive patients receiving allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Double filtration plasmapheresis combined with rituximab for donor-specific antibody desensitization in haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2023.
[Graft failure in allogeneic hematopoietic stem cell trans-plantation]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2018;47(6):651-658.
. Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis. J Transl Med. 2023;21(1):329.
HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma. Cell Transplant. 2023;32:9636897231194265.
The incidence, Risk factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019.
. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study. J Transl Med. 2024;22(1):410.
A novel strategy for the prevention of HBV-related hepatitis following allogeneic hematopoietic stem cell transplantation from HBsAg-positive donors lantation from HBsAg-positive donors. Biol Blood Marrow Transplant. 2020.
. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring Rearrangement and Its Prognostic Factors. Cell Transplant. 2024;33:9636897231225821.
Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2023.
Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma. Bone Marrow Transplant. 2024.
. Survival and late mortality among patients who survived disease-free for 2 years after stem cell transplantation. Br J Haematol. 2023.
TP53 in MDS and AML: Biological and clinical advances. Cancer Lett. 2024:216767.
.